Tall Cell Variant of Papillary Thyroid Cancer (TCV)

  • These tumors account for approximately 1% of papillary thyroid cancers and are typically associated with a V600E mutation in the BRAF gene
  • Most patients have evidence of disease after initial therapy, and the five-year mortality higher than in patients with classical papillary thyroid cancers
  • This variant is characterized by:
    • Elongated tumor cells (height twice the widthlining the papillary structuresinvolving at least 50% of the tumor
  • Proper identification of this variant is critical:
    • As it is associated with a more aggressive phenotype
  • They are characterized by:
    • Tumor cells with eosinophilic cytoplasm that are twice as tall as they are wide
  • TCV is more likely to present with:
    • Larger tumors
    • Lymph node
    • Distant metastases
    • Extracapsular extension
  • Mortality is significantly higher than for classic PTC:
    • Although it is not known why these tumors are more aggressive, it could be related to their molecular profile:
      • As many as 80% may express BRAF 
    • In addition, these tumors are frequently PET positive and radioiodine refractory

#Arrangoiz #ThyroidSurgeon #CancerSurgeon #SurgicalOncologist #HeadandNeckSurgeon #EndocrineSurgery #ThyroidCancer #TallCellVariantofPapillaryThyroidCancer #Miami #Mexico #MountSinaiMedicalCenter

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s